Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

Malignant tumors other than esophageal cancer (cured localized tumors, including cervical carcinoma in situ, skin basal cell carcinoma and prostate carcinoma in situ, were not excluded) had occurred within 5 years before randomization; Prostate cancer patients receiving hormone therapy with DFS for more than 5 years were not excluded).

Patients with high blood tendency who had a history of gastrointestinal bleeding within 6 months before randomization, or had coagulopathy at the time of enrollment, or were receiving thrombolysis or anticoagulant therapy;

Previous history of interstitial lung disease or pneumonia requiring steroid treatment at enrollment;

Had active tuberculosis at the time of randomization, or had received anti-tuberculosis therapy within 1 year before randomization;